menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Former Amryt Pharma Leadership Team join Poolbeg

    ACCESSWIRE

    High Court of Justice of England and Wales Sanctions Scheme of Arrangement

    GLOBENEWSWIRE

    Amryt Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici

    GLOBENEWSWIRE

    Amryt Publishes Announces Shareholder Meetings to Vote On Chiesi Acquisition

    GLOBENEWSWIRE

    After Amryt buy, Chiesi names Baxter vet Accogli its new CEO

    FIERCE PHARMA

    Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout

    FIERCE PHARMA

    Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc

    GLOBENEWSWIRE

    Amryt Announces Positive Top Line Results from Ph3 Pediatric Trial of Lomitapide

    GLOBENEWSWIRE

    Amryt Pharmaceuticals`s Mycapssa (octreotide) Receives Approval in Europe

    EMA

    COMP Adopts Positive Opinion on Orphan Designation for Mycapssa

    GLOBENEWSWIRE

    Amryt Announces New Patent for Mycapssa®

    GLOBENEWSWIRE

    Amryt Supports Global EB Awareness Week 2022

    GLOBENEWSWIRE

    Amryt to Report Q3 2022 Results on November 3, 2022

    GLOBENEWSWIRE

    Amryt Receives Reimbursement Approval from the Dutch Ministry for Myalepta

    GLOBENEWSWIRE

    CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly

    GLOBENEWSWIRE

    Amryt Announces New Patent for Mycapssa®

    GLOBENEWSWIRE

    Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (

    GLOBENEWSWIRE

    Amryt Receives ODD from FDA for Mycapssa for Carcinoid Syndrome

    GLOBENEWSWIRE

    Amryt Presents New Analyses from EASE PIII Trial in Epidermolysis Bullosa

    GLOBENEWSWIRE

    Amryt Pharma`s Filsuvez (birch bark extract) Receives Approval in the EMA

    FDA

    Amryt Pharmaceutical`s Filsuvez Receives Approval in Europe

    EMA

    Results of Annual General Meeting

    GLOBENEWSWIRE

    Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

    GLOBENEWSWIRE

    Amryt submits formal dispute resolution to FDA over rejected skin disease drug

    ENDPTS

    Amryt to Present Data from PIII Trials Open Label Extension of Mycapssa

    GLOBENEWSWIRE

    Posting of Annual Report and Notice of AGM

    GLOBENEWSWIRE

    Amryt Announces Details of EMA Contingent Value Rights Payment

    GLOBENEWSWIRE

    Amryt Announces New Patent for Mycapssa®

    GLOBENEWSWIRE

    Amryt Reports Record Q1 2022 Results

    GLOBENEWSWIRE

    CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic

    GLOBENEWSWIRE

    Amryt to Report Q1 2022 Results on May 4, 2022

    GLOBENEWSWIRE

    Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa

    GLOBENEWSWIRE

    Amryt Announces Positive Interim Analysis Data From EASE Phase 3 Trial in EB

    GLOBENEWSWIRE

    Amryt says 22% growth in FY 2021 Revenues to $222.5M

    GLOBENEWSWIRE

    Amryt says Successful Bioavailability Study for Mycapssa® (octreotide capsules)

    GLOBENEWSWIRE

    U.S. FDA declines to approve Amryt`s topical gel for rare skin diseases

    REUTERS

    Amryt Supports Rare Disease Day 2022

    GLOBENEWSWIRE

    Amryt to Report FY and Q4 2021 Results on March 9, 2022

    GLOBENEWSWIRE

    Amryt Completes $125 Million Non-Dilutive Debt Refinancing

    GLOBENEWSWIRE

    Another delay at Amryt as EMA calls in experts to inform review

    FIERCEBIOTECH

    Amryt Announces New Patents for Oleogel-S10

    GLOBENEWSWIRE

    Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa

    GLOBENEWSWIRE

    Amryt Provides Update on Regulatory Review Process for Oleogel-S10

    GLOBENEWSWIRE

    Amryt Announces the Cancellation of Admission of its Ordinary Shares

    GLOBENEWSWIRE

    Amryt Announces New Patents for Oleogel-S10 and Mycapssa®

    GLOBENEWSWIRE

    Amryt Issues Ordinary Shares and Total Voting Rights

    GLOBENEWSWIRE

    Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT

    GLOBENEWSWIRE

    Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT

    GLOBENEWSWIRE

    Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance

    GLOBENEWSWIRE

    Amryt Successfully Completes Acquisition of Chiasma

    GLOBENEWSWIRE

    Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6

    GLOBENEWSWIRE

    Publication of Circular to Amryt Shareholders in relation to Chiasma acquisition

    GLOBENEWSWIRE

    Amryt Pharma Announces update on Proposed Acquisition of Chiasma, Inc.

    GLOBENEWSWIRE

    FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting

    GLOBENEWSWIRE

    Amryt Pharma to Acquire Chiasma, to Further Strengthen Global Leadership

    GLOBENEWSWIRE

    Amryt Announces Results from an Investigator Sponsored Study of Lomitapide

    GLOBENEWSWIRE

    Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept®

    FT

    Amryt Pharma signs another distribution deal with Medison

    SHARECAST

    Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements

    GLOBENEWSWIRE

    Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.